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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 75, Revision 1 
(FGE.75Rev1): Consideration of tetrahydrofuran derivatives evaluated by 
JECFA (63rd meeting) structurally related to tetrahydrofuran derivatives 
evaluated by EFSA in FGE.33 (2008)1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) of the EFSA was 
requested to consider evaluations of flavouring substances assessed since 2000 by the Joint FAO/WHO Expert 
Committee on Food Additives (the JECFA), and to decide whether further evaluation is necessary, as laid down 
in Commission Regulation (EC) No 1565/2000. The present consideration concerns a group of 10 
tetrahydrofuran derivatives and one furanone derivative evaluated by the JECFA at the 63rd meeting in 2004. 
This revision is made due to additional toxicity data have become available for anhydrolinalool oxide (5) [FL-
no: 13.097]. The substances were evaluated through a stepwise approach that integrates information on 
structure-activity relationships, intake from current uses, toxicological threshold of concern, and available data 
on metabolism and toxicity. The JECFA concluded all the 11 tetrahydrofuran derivatives at step A3. The Panel 
agrees with the application of the Procedure as performed by the JECFA for 10 of the 11 substances. For the 
remaining substance [FL-no: 13.097] the Panel did not find that it could be metabolised to innocuous products 
and should accordingly be evaluated via the B-side of the Procedure scheme. A no observed adverse effect level 
(NOAEL) of 52 mg/kg body weight was derived from a 90-day study in rats and compared with an exposure 
estimate of 0.9 µg/ capita / per day for anhydrolinalool oxide a margin of safety of 3.5 × 106 was calculated. 
Accordingly, the Panel agrees with the JECFA conclusion ‘No safety concern at estimated level of intake as 
flavouring substances’ based on the maximised survey-derived daily intake (MSDI) approach. The 
specifications for the materials of commerce have also been considered and for all 11 substances, the 
information is adequate. 
© European Food Safety Authority, 2016 
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SUMMARY  
Following a request from the European Commission, the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion to provide 
scientific advice to the Commission on the implications for human health of chemically defined 
flavouring substances used in or on foodstuffs in the Member States. In particular, the Panel was 
requested to consider the Joint FAO/WHO Expert Committee on Food Additives (the JECFA) 
evaluations of flavouring substances assessed since 2000, and to decide whether no further evaluation 
is necessary, as laid down in Commission Regulation (EC) No 1565/2000. These flavouring 
substances are listed in the Register, which was adopted by Commission Decision 1999/217/EC and 
its consecutive amendments. 
In Flavouring Group Evaluation 75 (FGE.75), the European Food Safety Authority (EFSA) considered 
11 substances in the JECFA flavouring group of tetrahydrofuran and furanone derivatives. The Panel 
concluded that the 11 substances evaluated by the JECFA were structurally related to the six 
tetrahydrofuran derivatives evaluated by EFSA in Flavouring Group Evaluation (FGE.33). This 
revision of FGE.75 (FGE.75Rev1) is made because EFSA received additional toxicity data for the 
candidate substance anhydrolinalool oxide [FL-no: 13.097].   
Seven other substances were also evaluated by the JECFA in this group, but two are not in the 
Register [2-hexyl-4-acetoxytetrahydrofuran (JECFA-no: 1440) and (+/-)-2-(5-methyl-5-
vinyltetrahydrofuran-2-yl)propionaldehyde (JECFA-no: 1457)] and five substances [FL-no: 13.010, 
13.084, 13.085, 13.089 and 13.099] are α,β-unsaturated furanone and will be considered together with 
other α,β-unsaturated aldehydes and ketones in a separate FGE (EFSA CEF Panel, 2015). This 
consideration will, therefore, only deal with 11 JECFA-evaluated substances.  
The JECFA reached a conclusion for all 11 substances at step A3 of their procedure. The Panel agrees 
with the application of the Procedure as performed by the JECFA for 10 of the 11 substances. For the 
remaining substance [FL-no: 13.097], the Panel did not find that it could be metabolised to innocuous 
products and should accordingly be evaluated via the B-side of the Procedure scheme. A no observed 
adverse effect level (NOAEL) of 52 mg/kg body weight (bw) was derived from a 90-day study in rats 
and compared with an exposure estimate of 0.9 µg/capita per day for anhydrolinalool oxide a margin 
of safety of 3.5 × 106 can be calculated. Accordingly, the Panel agrees with the JECFA conclusion ‘No 
safety concern at estimated level of intake as flavouring substances’ based on the maximised survey-
derived daily intake (MSDI) approach. 
For all 11 substances, the JECFA evaluation is based on MSDI values derived from production figures 
from the European Union (EU). 
In order to determine whether the conclusion for the JECFA-evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications: 
Adequate specifications including complete purity criteria and identity are available for all 11 JECFA-
evaluated substances.  
Thus, for all 11 substances [FL-no: 13.007, 13.020, 13.042, 13.048, 13.049, 13.060, 13.090, 13.095, 
13.097, 13.140 and 13.166], the Panel agrees with the JECFA conclusion ‘No safety concern at 
estimated levels of intake as flavouring substances’ based on the MSDI approach 
For all substances, evaluated through the Procedure, use levels are needed to calculate the modified 
theoretical added maximum daily intake (mTAMDIs) in order to identify those flavouring substances 
that need more refined exposure assessment and to finalise the evaluation. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/20084 of the European Parliament 
and the Council of 16 December 2008 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012.5 The list contains flavourings substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000.6 
The European Food Safety Authority (EFSA) has considered the Joint FAO/WHO Expert Committee 
on Food Additives (the JECFA) evaluation of 11 tetrahydrofuran and furanone derivative in the 
flavouring group evaluation 75 (FGE.75). The opinion was adopted on 1 April 2008. 
EFSA concluded in its opinion that for anhydrolinalool oxide (5) [FL-no 13.097] it did not find that it 
could be metabolised to innocuous products and should accordingly be evaluated via the B-side of the 
Procedure scheme. No observed adverse effect level (NOAEL) could not be identified for the 
substance itself or for structurally related substances, and accordingly, additional data are required for 
this substance. 
EFSA has considered the JECFA evaluation of 15 flavouring substances consisting of aliphatic, 
acyclic and alicyclic terpenoid tertiary alcohols and structurally related substances in the flavouring 
group evaluation 90 (FGE.90). The opinion was adopted in 24 September 2009.7 
EFSA concluded in its opinion that for the 6-hydroxydihydrotheaspirane [FL-no 13.076] and 6-
acetoxydihydrotheaspirane [FL-no 13.087] no metabolism data are available, neither for the 
substances themselves nor for the related substances. Therefore, in contrast to the JECFA, EFSA 
cannot conclude that these substances are metabolised to innocuous products and they should 
accordingly be evaluated via the B-side of the Procedure scheme. NOAEL could not be identified for 
these two substances or for structurally related substances, and accordingly, additional data are 
required. 
The requested information on one representative material, anhydrolinalool oxide (5) [FL-no 13.097] 
has now been submitted by the European Flavour Association. This information is intended to cover 
the re-evaluation of this substance and of the two substances 6-hydroxydihydrotheaspirane [FL-no 
13.076] and 6-acetoxydihydrotheaspirane [FL-no 13.087]. 
The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substances. 
                                                     
4  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50. 
5  EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting 
the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the 
Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and 
repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161. 
6  Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16. 
7  EFSA Journal 2010;8(2):1336 
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TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requested EFSA to carry out a safety assessment on the following three 
flavouring substances: anhydrolinalool oxide (5) [FL-no 13.097], 6-hydroxydihydrotheaspirane [FL-
no: 13.076] and 6-Acetoxydihydrotheaspirane [FL-no: 13.087] in accordance with Commission 
Regulation (EC) No 1565/2000.   
ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000, hereafter named the ‘EFSA Procedure’. This Procedure 
is based on the opinion of the Scientific Committee on Food (SCF, 1999), which has been derived 
from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999), hereafter named the ‘JECFA 
Procedure’. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the 
Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be evaluated through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the ‘maximised survey-derived daily intake’ (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, the MSDI figures only from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case, the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting, 
considered ‘how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods’ (JECFA, 2006b). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a ‘modified theoretical added maximum daily intake’ (mTAMDI) 
approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
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Threshold of 1.5 µg/person per day (step B5) used by the JECFA 
The JECFA uses the threshold of concern of 1.5 µg/person per day as part of the evaluation procedure: 
‘The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 µg/person per day 
would not be expected to present a safety concern. The Committee recommended that the Procedure 
for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended to include 
the last step on the right-hand side of the original procedure (‘Do the condition of use result in an 
intake greater than 1.5 microgram per day?’)’ (JECFA, 1999).  
Consistent with the opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel 
does not make use of this threshold of 1.5 µg/person per day. 
Genotoxicity 
As reflected in the opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible 
genotoxic potential of the flavouring substances or of structurally related substances. Generally, 
substances for which the Panel has concluded that there is an indication of genotoxic potential, in 
vitro, will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. 
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through 
the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, as the Panel requests information on e.g. isomerism. 
Structural relationship  
In the consideration of the JECFA-evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
1. History of the evaluation of the substances in the present FGE 
At its 63rd meeting, the JECFA evaluated a group of 18 flavouring substances consisting of 
tetrahydrofuran and furanone derivatives. Two substances were not in the Register, and five are α,β-
unsaturated ketones and these have to be considered together with other α,β-unsaturated substances. 
The remaining 11 flavouring substances have originally been considered by EFSA in FGE.75 (EFSA, 
2008b). 
FGE Opinion adopted 
by EFSA 
Link No. of candidate 
substances 
FGE.75 1 April 2008 http://www.efsa.europa.eu/en/efsajournal/pub/917.htm 11 
FGE.75Rev1   11 
The present revision of FGE.75, FGE.75Rev1 includes the consideration of additional toxicity data 
provided for one representative substance anhydrolinalool oxide (5) [FL-no: 13.097]. The data 
provided are a 90-day study (Bauter, 2013). The new information on [FL-no: 13.097] is described in 
Section 5. 
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As the publication of FGE.75, new information on the stereoisomeric composition has been provided 
for the 11 substances [FL-no: 13.007, 13.020, 13.042, 13.048, 13.049, 13.060, 13.090, 13.095, 13.097, 
13.140 and 13.166], solubility data for three substances [FL-no: 13.042, 13.097 and 13.140] and 
poundage data on one substance [FL-no: 13.060] (EFFA, 2010). 
2. Presentation of the substances in the JECFA Flavouring Group 
2.1. Description 
2.1.1. JECFA status 
The JECFA has at the 63rd meeting evaluated a group of 18 flavouring substances consisting of 
tetrahydrofuran and furanone derivatives (JECFA, 2006a). 
2.1.2. EFSA considerations 
Two of the JECFA-evaluated substances are not in the Register [2-hexyl-4-acetoxytetrahydrofuran 
(JECFA-no: 1440) and (+/-)-2-(5-methyl-5-vinyltetrahydrofuran-2-yl) propionaldehyde (JECFA-no: 
1457)] and five substances [FL-no: 13.010, 13.084, 13.085, 13.089 and 13.099] are α,β-unsaturated 
ketones and will be considered together with other α,β-unsaturated aldehydes and ketones (EFSA, 
2015). This consideration will therefore only deal with 11 JECFA-evaluated substances.  
The Panel concluded that the 11 substances in the JECFA evaluated group of tetrahydrofuran and 
furanone derivatives are structurally related to six tetrahydrofuran derivatives evaluated by EFSA in 
the Flavouring Group Evaluation 33 (FGE.33). 
2.2. Isomers 
2.2.1. Status 
All substances in the JECFA evaluated group of tetrahydrofuran derivatives have one or more 
chiral centres. 
2.2.2. EFSA considerations 
Adequate information on isomeric composition is available for all the substances in FGE.75Rev1. 
2.3. Specifications 
2.3.1. JECFA status 
JECFA specifications are available for all substances (JECFA, 2005) (see Table 1). 
2.3.2. EFSA considerations 
The available specifications are considered adequate for all substances in FGE.75Rev1 (see Section 
2.2 and Table 1). 
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3. Intake estimations 
3.1. JECFA status 
For all substances evaluated through the JECFA Procedure intake data are available for the EU (see 
Table 6).  
3.2. EFSA considerations 
Annual production volumes as provided by industry (EFFA, 2010; EFFA, 2012a) can be used to 
calculate MSDIs for EU. For all substances normal and maximum use levels are needed to calculate 
the mTAMDIs. 
4. Genotoxicity data 
4.1. Genotoxicity studies – Text taken8 from the JECFA (JECFA, 2006a) 
In vitro 
No evidence was found for reverse mutation in tests in Salmonella Typhimurium strains TA1535, 
TA1537, TA1538, TA100, TA98 and TA102 with tetrahydrofurfuryl alcohol (1–102,100 µg/plate) 
[FL-no: 13.020], tetrahydrofurfuryl propionate (≤3,600 µg/plate) [FL-no: 13.049] or 2-(3-
phenylpropyl)tetrahydrofuran (≤3,600 µg/plate) [FL-no: 13.007] (Wild et al., 1983; Aeschbacher et 
al., 1989). 
Conclusion on genotoxicity 
After consideration of the available data, the JECFA concluded that it is highly unlikely that 
tetrahydrofurans would pose any significant genotoxic risk to humans under the conditions of use as 
flavouring agents. 
For a summary of in vitro/in vivo genotoxicity data considered by JECFA, see Table 2. 
4.2. Genotoxicity studies – Text taken9 from FGE.33 (EFSA, 2008a) 
In vitro 
Data from in vitro genotoxicity tests were available for one candidate substance and three supporting 
substances.  
A good quality reverse mutation assay using the candidate substance 3,6-dimethyl-2,3,3a,4,5,7a-
hexahydrobenzofuran [FL-no: 13.198] in Salmonella Typhimurium strains TA1535, TA1537, TA102, 
TA100 and TA98 gave negative results at concentrations of up to 316 µg/plate (Stien, 2005). 
Three valid, but limited reverse mutation assays were available for three supporting substances [FL-
no: 13.007, 13.020 and 13.049]. At concentrations of up to 3,600 µg/plate, two substances [FL-no: 
13.007 and 13.049] gave negative results using S. Typhimurium strains TA1535, TA1537, TA1538, 
TA100 and TA98 (Wild et al., 1983). At concentrations of up to 100 mg/plate, one supporting 
substance [FL-no: 13.020] produced negative results using S. Typhimurium strains TA100, TA102 
and TA98 (Aeschbacher et al., 1989). 
                                                     
8  The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
9  The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
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A positive result was seen in a sister chromatid exchange (SCE) study on the supporting substance 
1,8-cineole [FL-no: 03.001] (Galloway et al., 1987). This study was only positive without S9 
activation and at levels of 1,8-cineole of 200 and 500 µg/ml, which induced cell cycle delay and 
therefore was cytotoxic. There are several other genotoxicity tests on this substance, including another 
SCE study (although the concentrations of test substance were much lower in this study), that have 
given negative results. In the light of these results in several genotoxicity studies at gene and 
chromosomal level, the positive result in the SCE assay by Galloway (Galloway et al., 1987) is 
considered not to be of relevance for the overall evaluation. It is therefore concluded that 1,8-cineole is 
not genotoxic. 
Negative results on the structurally related 2-methyltetrahydrofuran [FL-no: 13.158] were seen in 
Ames test with S. Typhimurium strains TA97, TA98, TA100, TA102, TA1535 and TA1537 (CCRIS, 
2002; NTP, 2003). 
In vivo 
One in vivo genotoxicity study was available on the supporting substance tetrahydrofurfuryl 
propionate [FL-no: 13.049] with negative results. This micronucleus assay using doses of 316-949 
mg/kg body weight (bw) was not considered valid as only one time point was assessed, no PCE/NCE 
ratio was given and no positive control was used (Wild et al., 1983). 
Conclusion on genotoxicity 
Genotoxicity data are available only for a limited number of substances and the genotoxicity could not 
be assessed adequately. However, the data available do not preclude the evaluation of the candidate 
substances using the Procedure. 
For a summary of in vitro/in vivo genotoxicity data considered by EFSA, see Table 3 and 4. 
4.3. EFSA considerations 
After consideration of the limited data available, the Panel concluded these data do not preclude 
evaluation of the 11 flavouring substances in the present group of JECFA-evaluated tetrahydrofuran 
derivatives using the Procedure. 
5. 14-day and 90-day toxicity studies on anhydrolinalool oxide (5) [FL-no: 13.097] 
A 90-day study requested in the previous version of this FGE were submitted for [FL-no: 13.097] by 
the Industry (Bauter, 2013) along with a 14-day study (Bauter, 2012). 
5.1. 14-day toxicity study on anhydrolinalool oxide (5) [FL-no: 13.097] 
In a 14-day dietary study (Bauter, 2012), groups (3/sex per dietary intake level) of male and female 
Hsd:SD® rats were fed a diet designed to provide 0 (dietary control), 4,500, 9,000 and 18,000 ppm of 
anhydrolinalool oxide daily. The feed concentrations correspond to intakes of 362, 633 and 1,189 
mg/kg bw/day for males and 386, 662 and 921 mg/kg bw/day for females according to the study report 
based on measured feed intake and initial concentration of the substance in the feed. The Panel noted 
that the actual exposure was lower because of loss of the candidate substance from the feed during the 
week of exposure (see 90-day study below). Clinical observations were recorded daily and body 
weights and food consumption observations were made on days 0, 7 and 14. No mortality was 
observed throughout the course of the study and the general condition of the rats was unremarkable 
with exception of one 18,000 ppm female which showed a moderate hunched posture, slight to 
moderate piloerection and slight to moderate emaciation during days 7–14. There were statistically 
significant reductions in body weight gain and food consumption and efficiency for both sexes of the 
9,000 and 18,000 ppm groups. No gross pathology was related to the test substance in the diet. There 
were incidental findings in one female each in the 9,000 and 18,000 ppm groups, which had fluid-
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filled uteri and oviducts. Two females in the mid-dose group had uterine cysts but this was not 
attributed to the test material. 
5.2. 90-day toxicity study on anhydrolinalool oxide [FL-no: 13.097] 
  
In an OECD TG 408 compliant 90-day study, four groups of rats (10/sex per group) of male and 
female CRL Sprague–Dawley CD®IGS rats were fed a diet designed to provide 0 (dietary control), 
700 (low dose), 3,500 (mid dose) and 7,000 (high dose) mg of anhydrolinalool oxide per kg feed daily 
(Bauter, 2013). Dose selection was based on the findings in the 14-day study presented in above. 
These dietary levels correspond to the estimated daily intake of 0, 46, 233 and 453 mg/kg body weight 
for males and 0, 53, 257 and 506 mg/kg bw for females, respectively. The diets were replaced once a 
week. At the end of the first week, the concentrations of the test substance in the diet had decreased to 
27, 22 and 23% of the targeted levels, respectively. Therefore, the Panel decided to use intake levels 
adjusted to the concentrations determined at the end of this first week, corresponding to  daily intakes 
of 12.5, 52 and 105 mg/kg bw, respectively, for males and 14.5, 57 and 118  mg/kg bw, respectively, 
for females over the entire study duration.  
Clinical observations of toxicity were performed on day 0 and weekly until sacrifice. Animals were 
weighed on day 0 at the start of the study and weekly thereafter. Food consumption and efficiency 
were measured and calculated weekly. Blood chemistry and haematology were performed on blood 
drawn via sublingual bleed during week 12 after overnight fast. Urine was collected during the 15 
hours prior to the blood draw. At termination of the study, all survivors were sacrificed and subject to 
full necropsy. Tissues were weighed wet and analysed according to guidelines.  
There were no mortalities, clinical or ophthalmological changes associated with anhydrolinalool oxide 
in the diet. There was a concentration-dependent, statistically significant reduction in mean body 
weight for both males and females in the dietary exposure groups. At the end of the study, body 
weights were 100 (low dose), 91 (mid dose) and 83% (high dose) for males and 101, 92 and 89% for 
females, as compared to the average body weights of the animals in the control group. For males and 
females, the mid and high intake levels were reported to show concentration-dependent decreases in 
food consumption. The relative food consumptions for days 0–91 were 97 (low dose), 90 (mid dose) 
and 82% (high dose) for males and 97, 86 and 82% for females. Based on food consumption and body 
weight gain data, the food efficiency (i.e. the amount of food needed for one gram of body weight 
increase) was calculated. For the males treated with the high dose the average food efficiencies were 
significantly decreased by approximately 12% for the entire duration of the study (i.e. total increase in 
body weight/total food consumption, as compared to the males in the control group). The food 
efficiencies in the other dose groups (males as well as females) were not affected. According to the 
study authors, the reduction in body weight is likely to be related to these reduced food consumptions.  
Haematology parameters of note were reduced haematocrit levels in the high intake group males and 
increased platelet counts for the middle and high intake group of males. Neither of these differences 
occurred with a macroscopic or histopathology correlate and were considered incidental. All female 
test groups were comparable to concurrent controls with respect to haematology parameters. Males in 
the high dietary level group were reported to show increased blood urea nitrogen and creatinine levels 
which are most likely related to nephropathy discussed below. Males also were reported to show 
decreased serum triglyceride levels which was small in magnitude with no pathology correlate and 
considered incidental. Females were reported to show increased serum cholesterol levels in the high 
intake group but there was no associated pathology so this was considered incidental and not directly 
related to the test material in the diet. A statistically significant decrease in prothrombin time was 
reported for the high intake males but it was within historical control levels. At necropsy, gross 
findings in male and female test and control groups were reported to be sporadic, spontaneous and 
considered unrelated to anhydrolinalool oxide in the diet. 
Pronounced toxicity was observed in male rat kidneys. Microscopic observations attributed to test 
substance administration included: Kidney nephropathy in 2/10  control males, 9/10 low-dose males, 
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10/10 mid-dose males and 10/10 high-dose males characterised microscopically by regeneration of 
proximal cortical tubules with thickened basement membranes, mononuclear cell infiltrates and/or 
tubular casts. The intensity of the nephropathy was minimal in 2/2 control males, 9/9 low-dose males, 
5/10 mid-dose males and 4/10 high-dose male findings. The intensity of the nephropathy was slight in 
5/10 mid-dose males and 6/10 high-dose males. Eosinophilic cytoplasmic droplets of minimal degree 
were noted in proximal tubules of 6/10 low-dose males, 6/10 mid-dose males and 6/10 high-dose 
males. The morphologic appearance of nephropathy along with the presence of cytoplasmic droplets in 
proximal tubules was, according to Bauter et al (2015), consistent with alpha-2-microglobulin 
nephropathy syndrome. This was further confirmed by staining with the Mallory–Heidenhain method: 
a dose-dependent increase in staining intensity of positive cytoplasmatic droplets in the proximal 
convoluted tubules was observed in male rats. In female rats, no such kidney toxicity was observed, 
and the Mallory–Heidenhain staining was negative in the microscopic slides from female kidneys at 
the highest dose.  
Although no specific immunohistochemical staining of α2u globulin has been done to confirm the 
presence of this protein, the Panel considers the evidence sufficient to conclude that this kidney 
toxicity in male rats exclusively is not relevant for humans (Capen et al. 1999).  
The Panel considers that the decreases in final body weights in the high dose females may be 
attributed to the reduced food consumption and to some also in the high dose males. However, the 
change in food efficiency, which was observed for the males in the high dose group, may indicate an 
adverse effect on the animal physiology. Since there is insufficient information to attribute this effect 
to the renal changes (see above) the reduced food efficiency cannot be disregarded with respect to 
relevance for humans. In addition, the reduced food efficiency in the high dose group males is not 
caused by reduced food efficiency in individuals with nephropathy. Therefore, in contrast with the 
study authors, the Panel considered that the NOAEL from this study is the mid dose administered to 
the males i.e. 52 mg/kg bw per day. 
For a summary of subchronic and chronic toxicity data considered by EFSA, see Table 5. 
6. Application of the procedure 
6.1. Application of the procedure to 10 tetrahydrofuran derivatives and a furanone 
derivative by the JECFA (JECFA, 2006a) 
According to the JECFA, five of the substances belong to structural class II and six to structural class 
III using the decision tree approach presented by Cramer et al. (Cramer et al., 1978). 
The JECFA concluded all the 11 substances at step A3 in the JECFA Procedure, i.e. the substances are 
expected to be metabolised to innocuous products (step 2) and the intakes for all substances are below 
the thresholds for their structural classes II and III (step A3). 
In conclusion, the JECFA evaluated all substances to be of no safety concern at the estimated levels of 
intake as flavouring substances based on the MSDI approach. 
The evaluations of the 11 substances are summarised in Table 6. 
6.2. Application of the procedure to six tetrahydrofuran derivatives evaluated by EFSA in 
FGE.33: (EFSA, 2008a) 
Step 1 
All candidate substances are classified according to the decision tree approach by Cramer et al. 
(Cramer et al., 1978) into structural class III. 
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Step 2 
Four of the candidate substances [FL-no: 13.120, 13.167, 13.189 and 13.198] can be concluded to be 
metabolised to innocuous substances and will therefore proceed along the A-side of the Procedure.  
Two of the substances cannot be anticipated to be metabolised to innocuous products and proceeds via 
the B-side of the Procedure [FL-no: 13.182 and 16.054]. 
Step A3 
The MSDI of the four candidate substances [FL-no: 13.120, 13.167, 13.189 and 13.198] were 
estimated to be in the range from 0.0012 to 3.0 µg/capita per day, which are below the threshold of 
concern for structural class III of 90 µg/person per day. Therefore, it can be concluded that these 
substances would not be expected to be of safety concern.  
Step B3 
The MSDI of the two candidate substances [FL-no: 13.182 and 16.054] proceeding via the B-side 
were estimated to be 0.011 and 0.65 µg/capita per day, respectively, which are below the threshold of 
concern for structural class III of 90 µg/person per day. Therefore, these substances can proceed to 
step B4 of the Procedure. 
Step B4 
For the two candidate substances [FL-no: 13.182 and 16.054], a NOAEL could not be provided for the 
substances or for structurally related substances, and accordingly, additional data are required for these 
substances. 
Accordingly, four substances [FL-no: 13.120, 13.167, 13.189 and 13.198] do not pose a safety 
concern based on the MSDI approach, whereas for two substances [FL-no: 13.182 and 16.054] 
additional data are required. 
The stepwise evaluation of the six substances are summarised in Table 7. 
6.3. EFSA Considerations 
The JECFA reached its conclusions for all 11 tetrahydrofuran derivatives and the furanone derivative 
at step A3. The Panel agrees with the application of the Procedure as performed by the JECFA for 10 
of the 11 substances in accordance with the approach applied in FGE.33. For the remaining substance 
[FL-no: 13.097], the Panel did not find that the substance could be metabolised to innocuous products 
and should, accordingly, be evaluated via the B-side of the Procedure scheme. A NOAEL of 52 mg/kg 
bw was derived from a 90-day study in rats and compared with an exposure estimate of 0.9 µg/capita 
per day for anhydrolinalool oxide a margin of safety of 3.5 × 106 can be calculated. Accordingly, the 
Panel agrees with the JECFA conclusion ‘No safety concern at estimated level of intake as flavouring 
substances’ based on the MSDI approach. 
7. Conclusion 
The Panel has considered 10 tetrahydrofuran derivatives and a furanone derivative previously 
evaluated by JECFA . The Panel concluded that the 11 substances evaluated by the JECFA were 
structurally related to the six tetrahydrofuran derivatives evaluated by EFSA in Flavouring Group 
Evaluation 33 (FGE.33).  
Seven other substances were also evaluated by the JECFA in this group, but two are not in the 
Register [2-hexyl-4-acetoxytetrahydrofuran (JECFA-no: 1440) and (+/-)-2-(5-methyl-5-
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vinyltetrahydrofuran-2-yl)propionaldehyde (JECFA-no: 1457)] and five substances [FL-no: 13.010, 
13.084, 13.085, 13.089 and 13.099] are α,β-unsaturated furanones and will be considered together 
with other α,β-unsaturated aldehydes and ketones in a separate FGE (EFSA CEF Panel, 2015). This 
consideration will therefore only deal with 11 JECFA-evaluated substances. 
The JECFA concluded all 11 substances at step A3. The Panel agrees with the application of the 
Procedure as performed by the JECFA for 10 of the 11 substances. For the remaining substance [FL-
no: 13.097], the Panel did not find that it could be metabolised to innocuous products and should 
accordingly be evaluated via the B-side of the Procedure scheme. A NOAEL of 52 mg/kg bw was 
derived from a 90-day study in rats and compared with an exposure estimate of 0.9 µg/capita per day 
for anhydrolinalool oxide a margin of safety of 3.5 × 106 can be calculated. Accordingly, the Panel 
agrees with the JECFA conclusion ‘No safety concern at estimated level of intake as flavouring 
substances’ based on the MSDI approach.. 
For all 11 substances, the JECFA evaluation is based on MSDI values derived from production figures 
from the EU. 
In order to determine whether the conclusion for the JECFA-evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications: 
Adequate specifications including complete purity criteria and identity are available for all 20 JECFA-
evaluated substances (see Section 1.2).  
Thus, for all 11 substances [FL-no: 13.007, 13.020, 13.042, 13.048, 13.049, 13.060, 13.090, 13.095, 
13.097, 13.140 and 13.166], the Panel agrees with the JECFA conclusion ‘No safety concern at 
estimated levels of intake as flavouring substances’ based on the MSDI approach. 
For all substances evaluated through the Procedure, use levels are needed to calculate the mTAMDIs 
in order to identify those flavouring substances that need more refined exposure assessment and to 
finalise the evaluation. 
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Table 1:  Specification summary of the substances in the JECFA Flavouring Group of tetrahydrofuran derivatives (JECFA, 2006a) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formul
a 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index (d) 
Spec.gravity (e) 
EFSA comments 
13.007 
1441 
2-(3-
Phenylpropyl)tetrahydrofuran 
O
 
2898 
489 
3208-40-0 
Liquid 
C13H18O 
190.28 
Very slightly 
soluble 
Soluble 
105–107 (1 hPa) 
 
NMR 
98% 
1.511–1.516 
0.975–0.983 
 
Racemate (EFFA, 2010).  
13.020 
1443 
Tetrahydrofurfuryl alcohol O OH
 
3056 
2029 
97-99-4 
Liquid 
C5H10O2 
102.15 
Soluble 
Soluble 
178–179 
 
IR 
99% 
1.449–1.455 
1.050–1.052 
 
Racemate (EFFA, 2010).  
13.042 
1448 
4,5-Dihydro-2-methylfuran-
3(2H)-one 
O
O  
3373 
2338 
3188-00-9 
Liquid 
C5H8O2 
100.12 
Insoluble 
Soluble 
139 
 
NMR 
97% 
1.534–1.537 
1.180–1.185 
 
Change  the entry in the Union 
List to : 
 2-methyltetrahydrofuran-3-one 
Racemate (EFFA, 2010).  
13.048 
1444 
Tetrahydrofurfuryl butyrate 
O
O
O
 
3057 
11841 
2217-33-6 
Liquid 
C9H16O3 
172.23 
Insoluble 
Soluble 
227 
 
NMR 
97% 
1.446–1.452 
1.007–1.013 
 
Racemate (EFFA, 2010).  
13.049 
1445 
Tetrahydrofurfuryl 
propionate 
O
O
O
 
3058 
11843 
637-65-0 
Liquid 
C8H14O3 
158.20 
Insoluble 
Soluble 
207 
 
NMR 
97% 
1.435–1.441 
1.037–1.043 
 
Racemate (EFFA, 2010).  
13.060 
1447 
Tetrahydrofurfuryl 
cinnamate 
O
O
O
 
3320 
11821 
65505-25-
1 
Liquid 
C14H16O3 
232.28 
Insoluble 
Soluble 
>300 
 
NMR 
95% 
1.593–1.600 
1.107–1.113 
 
Racemate of mixture of (Z)- 
and (E)-isomer (EFFA, 2010). 
70-95 % E-form and 5-30 % Z-
form (EFFA, 2012b).  
13.090 
1452 
2,2-Dimethyl-5-(1-
methylprop-1-
enyl)tetrahydrofuran 
O
 
3665 
10937 
7416-35-5 
Liquid 
C10H18O 
154.25 
Slightly 
soluble 
Soluble 
65 (13 hPa) 
 
IR NMR MS 
98% 
1.446–1.451 
0.858–0.865 
 
Racemate of mixture of (Z)- 
and (E)-isomer (EFFA, 2010). 
50-80 % E-form and 20-50 % 
Z-form (EFFA, 2012b).  
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FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formul
a 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index (d) 
Spec.gravity (e) 
EFSA comments 
13.095 
1453 
2,5-Diethyltetrahydrofuran O
 
3743 
11882 
41239-48-
9 
Liquid 
C8H16O 
128.22 
Insoluble 
Soluble 
116 
 
NMR 
97% 
1.401–1.407 
0.827–0.833 
 
Mixture of stereoisomers 
(EFFA, 2010). cis (R,S) = (S,R) 
(50 %), trans (R,R) (25 %) and 
trans (S,S) (25 %) (EFFA, 
2012b).  
13.097 
1455 
Anhydrolinalool oxide (5) O
 
3759 
11944 
13679-86-
2 
Liquid 
C10H16O 
152.24 
Slightly 
soluble 
Soluble 
58 (17 hPa) 
 
IR NMR 
97% 
1.449–1.454 
0.874–0.878 
 
Name in Union List to be 
changed to anhydrolinalool 
oxide (5-ring)  
Mixture of enantiomers (EFFA, 
2010). 25% of each (EFFA, 
2012b).  
13.140 
1454 
Linalool oxide (5-ring) O OH
 
3746 
11876 
1365-19-1 
Liquid 
C10H18O2 
170.25 
Slightly 
soluble 
Soluble 
188 
 
NMR 
95% 
1.451–1.456 
0.932–0.942 
 
Mixture of enantiomers (EFFA, 
2010). 25% of each (EFFA, 
2012b).  
13.166 
1442 
Tetrahydrofurfuryl acetate 
O
O
O
 
3055 
2069 
637-64-9 
Liquid 
C7H12O3 
144.20 
Soluble 
Soluble 
194-195(979hPa) 
 
NMR 
97% 
1.435–1.440 
1.058–1.064 
 
Racemate (EFFA, 2010). 
(a) Solubility in water, if not otherwise stated. 
(b) Solubility in 95% ethanol, if not otherwise stated. 
(c) At 1013.25 hPa, if not otherwise stated. 
(d) At 20°C, if not otherwise stated. 
(e) At 25°C, if not otherwise stated. 
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Table 2:  Summary of genotoxicity data of tetrahydrofuran derivatives evaluated by the JECFA (JECFA, 2006a)  
FL-no 
JECF
A-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
In vitro 
13.007 
1441 
2-(3-
Phenylpropyl)tetrahydrofuran 
O Reverse 
mutation 
S. Typhimurium TA1535, TA1537, 
TA1538, TA100 and TA98 
≤3,600 µg/plate Negative(a) (Wild et al., 1983). 
13.020 
1443 
Tetrahydrofurfuryl alcohol O OH
 
Reverse 
mutation 
S. Typhimurium TA100 TA102 and 
TA98 
1–102,100 µg/plate(b)
 
Negative(a,c) (Aeschbacher et al., 
1989) 
13.049 
1445 
Tetrahydrofurfuryl propionate 
O
O
O Reverse 
mutation 
S. Typhimurium TA1535 TA1537, 
TA1538, TA100 
≤3,600 µg/plate Negative(d) 
 
(Wild et al., 1983) 
In vivo 
13.049 
1445 
Tetrahydrofurfuryl propionate 
O
O
O Micronucle
us formation 
Male and female mouse bone 
marrow(e) 
316, 632, 949 mg/kg 
bw 
Negative (Wild et al., 1983) 
(a) With or without metabolic activation provided by S9 (9,000 × g supernatant from rodent liver). 
(b) Calculated based on the relative molecular mass of tetrahydrofurfuryl alcohol = 102.1. 
(c) Modified pre-incubation method. 
(d) Without metabolic activation. 
(e) Administered intraperitoneally. 
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Table 3:  Genotoxicity (in vitro) EFSA/FGE.33 (EFSA, 2008a) (substances in brackets are JECFA-evaluated substances) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
(2-(3-
Phenylpropyl)tetrahydrofura
n [13.007]) 
Reverse mutation S. Typhimurium  
TA1535, TA1537, TA1538, TA100 
and TA98 
Up to 3,600 µg/plate Negative(a) (Wild et al., 1983)  
(Tetrahydrofurfuryl alcohol 
[13.020]) 
Reverse mutation S. Typhimurium  
TA100, TA102 and TA98 
1–102,100 µg/plate Negative(a,b) (Aeschbacher et al., 
1989) 
 
(Tetrahydrofurfuryl 
propionate [13.049]) 
Reverse mutation S. Typhimurium  
TA1535, TA1537, TA1538, TA100 
Up to 3,600 µg/plate Negative(c) 
 
(Wild et al., 1983)  
3,6- Dimethyl-2,3,3a,4,5,7a-
hexahydro-benzofuran 
[13.198] 
Reverse mutation S. Typhimurium  
TA1535, TA1537, TA102, TA100 
and TA98 
0, 3.16, 10, 31.6, 100, 316 µg 
/plate 
Negative(a) (Stien, 2005)  
(1,8-Cineole [03.001]) Reverse mutation S. Typhimurium  
TA100, TA102,  TA98 and TA97 
250–2,500 µg/plate Negative(a) (Gomes-Carneiro et al., 
1998) 
 
Reverse mutation S. Typhimurium  
TA1535, TA1537,  TA100 and TA98 
3.3–3,333 µg/plate Negative(a, b) (Haworth et al., 1983)  
Sister chromatid 
exchange 
Chinese hamster ovary cells 50–500 µg/ml 
600–800 µg/ml 
Positive(c)
Negative(d) 
(Galloway et al., 1987)  
Sister chromatid 
exchange 
Chinese hamster ovary cells K-1 10, 33.3 and 100 µmol/l 
(1.5, 5.1 and 15.4 µg/ml) 
Negative(c) (Sasaki et al., 1989)  
Chromosomal 
aberrations 
Chinese hamster ovary cells 479–663 µg/ml 
630–810 µg/ml 
Negative(c)
Negative(d) 
(Galloway et al., 1987)  
DNA repair Bacillus subtilis H17 (rec+) and M45 
(rec-) 
18 µg/disk Negative (Oda et al., 1979)  
DNA repair Bacillus subtilis H17 (rec+) and M45 
(rec-) 
< 20 µl/disk (20,000 µg/disk) Negative (Yoo, 1986)  
(a)  With or without metabolic activation 
(b) Modified pre-incubation method. 
(c) Without metabolic activation   
(d) With metabolic activation. 
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Table 4:  Genotoxicity (in vivo) EFSA/FGE.33 (EFSA, 2008a) (substances in brackets are JECFA-evaluated substances) 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments 
(Tetrahydrofurfuryl propionate 
[13.049]) 
Micronucleus 
formation 
Male and 
female mouse 
bone marrow 
Intraperitonea
l 
316, 632, 
949 mg/kg 
bw 
Negative (Wild et al., 1983) Study not considered valid. One time point 
only is used, no PCE/NCE ratio is provided, 
no positive control.  
Table 5:  Subchronic and chronic toxicity studies on [FL-no: 13.097] 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration 
(days)  
NOAEL 
(mg/kg bw/day) 
Reference Comments 
Anhydrolinalool oxide (5) 
[13.097] 
Rat;  
M/F 
6 
Diet 0, 362.1, 
633.4 and 
1,189 mg/kg 
bw/day for 
males and 0, 
385.5, 661.9 
and 921.2 
mg/kg 
bw/day for 
females 
14 - (Bauter, 2012)  
Rat; 
M/F 
20 
Diet 0, 12.5, 52 
and 105 
mg/kg bw 
for males 
and 0, 14.5, 
57 and 118 
mg/kg bw 
for females 
90 52 (Bauter, 2013) OECD (408) compliant 90-day study. Dose levels have 
bben corrected for loss from the feed. 
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Summary of safety evaluations 
Table 6:  Summary of safety evaluation of 11 tetrahydrofuran derivatives (JECFA, 2006a) 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI (a)  
US MSDI 
(g/capita per 
day) 
Class (b) 
Evaluation 
procedure path 
(c) 
Outcome 
on the 
named 
compound  
[(d) or (e)] 
EFSA conclusion on the named 
compound 
(Procedure steps, intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion 
on the material of 
commerce 
13.042 
1448 
4,5-Dihydro-2-methylfuran-
3(2H)-one 
O
O  
20.5 
9 
Class II 
A3: Intake below 
threshold 
(d) No safety concern at the estimated level 
of intake based on the MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
13.090 
1452 
2,2-Dimethyl-5-(1-
methylprop-1-
enyl)tetrahydrofuran 
O
 
9.4 
0.04 
Class II 
A3: Intake below 
threshold 
(d) No safety concern at the estimated level 
of intake based on the MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
13.095 
1453 
2,5-Diethyltetrahydrofuran O
 
0.009 
0.09 
Class II 
A3: Intake below 
threshold 
(d) No safety concern at the estimated level 
of intake based on the MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
13.097 
1455 
Anhydrolinalool oxide (5) O
 
0.9 
0.03 
Class II 
A3: Intake below 
threshold 
(d) No safety concern at the estimated level 
of intake based on the MSDI approach 
(Step B4) 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
13.140 
1454 
Linalool oxide (5-ring) O OH
 
72.5 
14 
Class II 
A3: Intake below 
threshold 
(d) No safety concern at the estimated level 
of intake based on the MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
13.007 
1441 
2-(3-
Phenylpropyl)tetrahydrofura
n 
O
 
0.0009 
0.7 
Class III 
A3: Intake below 
threshold 
(d) No safety concern at the estimated level 
of intake based on the MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
13.020 
1443 
Tetrahydrofurfuryl alcohol O OH
 
33 
22 
Class III 
A3: Intake below 
threshold 
(d) No safety concern at the estimated level 
of intake based on the MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
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FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI (a)  
US MSDI 
(g/capita per 
day) 
Class (b) 
Evaluation 
procedure path 
(c) 
Outcome 
on the 
named 
compound  
[(d) or (e)] 
EFSA conclusion on the named 
compound 
(Procedure steps, intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion 
on the material of 
commerce 
13.048 
1444 
Tetrahydrofurfuryl butyrate 
O
O
O
 
0.009 
0.2 
Class III 
A3: Intake below 
threshold 
(d) No safety concern at the estimated level 
of intake based on the MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
13.049 
1445 
Tetrahydrofurfuryl 
propionate 
O
O
O
 
0.051 
5 
Class III 
A3: Intake below 
threshold 
(d) No safety concern at the estimated level 
of intake based on the MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
13.060 
1447 
Tetrahydrofurfuryl 
cinnamate 
O
O
O
 
0.012 
0.01 
Class III 
A3: Intake below 
threshold 
(d) No safety concern at the estimated level 
of intake based on the MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
13.166 
1442 
Tetrahydrofurfuryl acetate 
O
O
O
 
0.6 
8 
Class III 
A3: Intake below 
threshold 
(d) No safety concern at the estimated level 
of intake based on the MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
(a) EU MSDI: Amount added to food as flavour in (kg/year) × 10E9 / (0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365)  =  µg/capita per day. 
(b) Thresholds of concern: Class I = 1800 µg/person per day, Class II = 540 µg/person per day, Class III = 90 µg/person per day. 
(c) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d) No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e) Data must be available on the substance or closely related substances to perform a safety evaluation. 
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Table 7:  Summary of safety evaluations applying the procedure (based on intakes calculated by the MSDI approach) (EFSA/FGE.33) 
FL-no EU Register name Structural formula MSDI (a)  
(g/capita per 
day) 
Class (b) 
Evaluation procedure path (c) 
Outcome on the 
named 
compound  
[(d) or (e)] 
Outcome on the 
material of 
commerce [(f), (g), 
or (h)] 
Evaluation 
remarks 
13.120 
 
2,5-
Dimethyltetrahydrofuran 
O
 
0.0012 
 
Class III 
A3: Intake below threshold 
(d) (g)  
13.167 
 
Tetrahydrofuryl 
phenylacetate O
O
O 0.12 
 
Class III 
A3: Intake below threshold 
(d) (g)  
13.189 
 
Linalool oxide(5) acetate 
O
O O
0.012 
 
Class III 
A3: Intake below threshold 
(d) (g)  
13.198 
 
3,6-Dimethyl-2,3,3a,4,5,7a-
hexahydro-benzofuran 
O 3.0 
 
Class III 
A3: Intake below threshold 
(d) (g)  
13.182 
 
2-Methyl-3-
thioacetoxytetrahydrofuran 
O
S
O
 
0.011 
 
Class III 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data 
required 
(g)  
16.054 
 
6-Methylene-2,10,10-
trimethyl-1-
oxaspiro[4.5]dec-7-ene 
O
0.65 
 
Class III 
B3: Intake below threshold, B4: 
No adequate NOAEL 
Additional data 
required 
(g)  
(a) EU MSDI: Amount added to food as flavour in (kg/year) × 10E9 / (0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365)  =  µg/capita per day 
(b) Thresholds of concern: Class I = 1800, Class II = 540, Class III = 90 µg/person per day 
(c) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d) No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e) Data must be available on the substance or closely related substances to perform a safety evaluation. 
(f) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
(g) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or 
information on stereoisomerism. 
(h) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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ABBREVIATIONS 
bw  body weight 
CAS  Chemical Abstract Service 
CEF  EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CoE  Council of Europe 
DNA  deoxyribonucleic acid 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  good laboratory practise 
ID  identity 
IR  infrared spectroscopy 
JECFA  the Joint FAO/WHO Expert Committee on Food Additives 
MSDI  maximised survey-derived daily intake 
mTAMDI modified theoretical added maximum daily intake 
NCE  normochromatic erythrocyte 
NOAEL no observed adverse effect level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PCE  polychromatic erythrocyte 
SCE  sister chromatid exchange 
SCF  Scientific Committee on Food 
WHO  World Health Organization 
